geniVida® brand genistein from DSM Nutritional Products has been shown to reduce levels of prostate specific antigen (PSA) in men with early prostate cancer. The study was conducted by Bato Lazerevic and colleagues at the Oslo University Hospital in Oslo and was recently published in Nutrition and Cancer, 1-10, 2011.
In Asian countries where diets include high soy consumption, the incidence and mortality of prostate cancer is significantly lower than in Western countries. Isoflavones, and specifically genistein, are considered to be the major components from soy responsible for this difference. To gain a better understanding of the role of genistein, Dr. Lazerevic and colleagues conducted a placebo-controlled, randomized, double blind study in 47 men with early prostate cancer and elevated PSA levels. PSA is present in small quantities in the serum of men with healthy prostates but the level tends to rise in the presence of prostate disorders, including prostate cancer.
The intention of the study was to determine if there were any measureable benefits resulting from supplementation with 30mg genistein per day, an intake that could also be achieved by consuming a soy-rich diet such as a traditional Japanese diet. Supplementation with 30mg of geniVida® brand pure aglycone genistein, during a period of three to six weeks, was shown to reduce PSA values in serum. This daily dose of geniVida® was well tolerated with no effects on hormone levels, such as testosterone. In addition, this supplementation lowered blood cholesterol levels. These findings could help to explain the reduced risk of prostate cancer in men consuming a diet high in soy products and the potential benefit of a 30mg per day geniVida® dietary supplement for men.
DSM – Bright Science. Brighter Living. ™
Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM’s 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com.